Global Hemodialysis Bloodline Systems Market - 2021-2028

Global Hemodialysis Bloodline Systems Market - 2021-2028

Market Overview

The Global ""Hemodialysis Bloodline Systems Market"" is Expected to reach at a CAGR of 8.0% during the forecast period (2021-2028).

A hemodialysis bloodline system is a tubing system used to connect a patient's blood circulation to a dialyzer during dialysis. Renal failure patients receive hemodialysis treatment. The technique involves the patient's blood flowing through a disposable bloodstream into a dialyzer, which filters the blood, eliminates waste items, adds anti-coagulants, and returns the purified blood to the patient's body.

Market Dynamics

The increasing prevalence of chronic kidney diseases, end-stage renal disease (ESRD), renal failure, and other conditions worldwide are expected to drive demand for hemodialysis bloodline systems during the forecast period. Growing research and development activities that result in the development of innovative products are likely to increase physician adoption of hemodialysis bloodline systems.

The increase in prevalance of End Stage Renal Disease cases in the market will drive the market growth

As the global incidence of End Stage Renal Disease rises, the demand for dialysis treatment is expected to rise. Every year, approximately 2 million people worldwide are affected by End Stage Renal Disease (Source: United States Renal Data System Annual Data Report, 2018). The global progression of renal diseases is expected to increase the demand for dialysis to maintain proper kidney function. The prevalence of kidney-related diseases is expected to rise significantly as the world's geriatric population grows rapidly. This, in turn, is expected to drive remarkable growth in the hemodialysis and peritoneal dialysis markets during the forecast period.

Kidney diseases affect approximately 195 million women worldwide.Chronic Kidney Disease (CKD) is the sixth-leading cause of death.Globally, it is estimated that 1.7 million people die each year due to acute kidney injury (AKI).(Source National Health Portal). Chronic kidney disease has been known as a major public health issue worldwide. The global estimated prevalence of chronic kidney disease is 13.4 percent (11.7-15.1 percent), and the number of patients with End Stage Kidney Disease who require renal replacement therapy ranges between 4.902 and 7.083 million. Chronic kidney disease directly impacts the global burden of morbidity and mortality due to its effect on cardiovascular risk and End Stage Kidney Disease.

Kidney failure affects nearly 750,000 patients in the United States each year, with 2 million patients worldwide.According to World Health Organization, Diabetes was the cause of 1.5 million deaths in 2019, with 48 percent of all diabetes-related deaths occurring before 70. As a result of the rising prevalence of chronic kidney disorders and kidney failure, there may be a greater demand for early diagnosis and treatment.This contributes to the growth of the global hemodialysis bloodline systems market.

Complications during dialysis is likely to hamper the market growth

Patients' main causes of death in dialysis are cardiac diseases (arrhythmic mechanisms or sudden cardiac arrest) and vascular access-related complications such as bleeding and infection, low blood pressure, nausea, hernia, hepatitis (B & C), and anemia.However these cases are very rare but they have a negative impact on the hemodylasis bloodline systems market. Also,high cost of treatment is the major drawback which is likely to hamper the market . Majority of under developed and developing countries are facing this problem

COVID-19 Impact Analysis

The coronavirus pandemic poses several challenges to clinical healthcare providers and patients worldwide. The increase in the number of COVID cases and the severity rate is likely to increase the incidence of kidney damage. The global demand for renal replacement fluids has increased significantly due to the pandemic. Compared to historical US populations, the demand for RRT among COVID-19 patients has increased fivefold (4.9 percent in 2020 vs. 0.9 percent previously) (Source: American Society of Nephrology, 2021). The gradual shift toward home hemodialysis treatment before the pandemic, as well as concerns about the spread of COVID-19 infection, has significantly increased patient interest in HD treatment.

Segment Analysis

The double needle therapy segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)

Over the projection period, the double needle therapy segment is expected to grow at the fastest CAGR, owing to the increased demand for dialysis, the rising number of diabetes patients and rising frequency of chronic disease such kidney failure, End Stage Renal Disease .For example, According to World Kidney Day, a global awareness campaign, chronic kidney disease affects 10% of the world's population. According to the Global Burden Study, Chronic kidney disease ranked 18th in the world regarding the total number of fatalities in 2019. Chronic kidney disease can progress to End Stage Renal Disease if left untreated. The National Kidney Foundation estimates that over 450,000 End Stage Renal Disease patients are on dialysis in the United States alone each year. As a result, dialysis is the most widely used treatment for kidney disease. The rising global prevalence of chronic kidney disease is a primary driving force behind the double-needle therapy segment.

Furthermore, According to the Centers for Disease Control and Prevention, roughly 26.7 million people, or 11.5 percent of all adults in the United States, were diagnosed with heart disease in 2019. Due to an increase in severe renal disease and comorbidities occurrences, this major patient group is anticipated to grow. Other factors, such as alcohol and cigarette use, obesity, and genetic and inherited factors, also contribute to the rise in the number of people with chronic kidney disease, which will increase the demand of double-needle therapy due to low complications post therapy.

Geographical Analysis

North America region holds the largest market share of global hemodialysis bloodline systems market

North America is expected to dominate the market in the forecast period. The established market players in the region will continue to account for a substantial share in the market throughout the forecast period. According to WHO research, high-income nations spend more than 2-3 percent of their annual healthcare budget on treating end-stage kidney disease, even though people receiving treatment account for less than 0.03 percent of the overall population. Furthermore, sophisticated healthcare infrastructure and the growing prevalence of infections will positively impact the hemodialysis bloodline systems growth in the forecast period.

However, Asia-Pacific is assessed to grow the fastest during the forecast period, owing to increased healthcare spending and increased awareness about various treatment options. The cost of public and private health care in these countries is predicted to rise. As a result, producers are more inclined to concentrate their efforts on these markets. According to the World Bank Group, China's healthcare spending was 5.5 percent of GDP in 2014, and the country's healthcare spending is predicted to double by 2023. The hemodialysis bloodstream systems market is driven by strong growth in healthcare spending and rising worldwide per capita income. Shortly, improvements in health care infrastructure and government reimbursement schemes in both developed and developing nations are expected to boost the hemodialysis bloodline systems market. Other factors that contribute to the market's growth include a large patient base of various chronic diseases such as kidney failure and End Stage Renal Disease, which necessitate the use of hemodialysis bloodline system, which contribute to the growth of the Asia-Pacific hemodialysis bloodline systems market

Competitive Landscape

The hemodialysis bloodline systems market is highly competitive with presence of local as well as global companies. Major players operating in the global hemodialysis bloodline systems market include Baxter, Fresenius, B.Braun ,Nipro , Nikkiso, Asahi KASEI Medical, Allmed. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the biopsy devices market globally. For instance in April 2018, Fresenius Medical Care AG & Co. KGaA, the main provider of bloodstream systems, won the Red Dot Award for product design for its 6008 CAREset, which demonstrated good therapeutic benefits.

Key Developments

In Feb 2019, The Medisystems Streamline Bloodlines business was acquired by B.Braun Medical Inc. The Streamline Bloodline for the Dialog + hemodialysis system, Streamline Bloodline for the Fresenius Medical Care hemodialysis system, and Streamline Bloodline Long for the Fresenius Medical Care hemodialysis system will be among the bloodline systems acquired.

In Feb 2019, Fresenius Medical Care AG & Co.KGaA completed the $ 2 billion acquisition of Nx Stage Medical, a US-based medical device manufacturer involved in developing, producing, and marketing medical devices for in-home dialysis and critical care.

Baxter

Overview: Baxter International Inc. is an American international health care corporation headquartered in Deerfield, Illinois. The company's main focus is on kidney illness and other chronic and urgent medical diseases. Baxter's BioScience division makes recombinant and blood plasma proteins for hemophilia and other bleeding diseases, as well as plasma-based therapies for immunological deficiencies and other chronic and acute blood-related ailments, regenerative medicine products, and vaccines. Baxter's Medical Products division makes intravenous goods and other devices for delivering fluids and pharmaceuticals to patients, as well as inhalational anesthetics, contract manufacturing services, and products for treating end-stage renal diseases, such as peritoneal dialysis and hemodialysis.

Product Portfolio:

THERANOVA: THERANOVA was created to filter a broader range of molecules from the blood than traditional hemodialysis filters, to remove large intermediate molecules (25 kDa to 45 kDa) linked to inflammation and cardiovascular health in patients with end-stage renal disease (ESRD). Its MEDIUM CUT-OFF (MCO) membrane widens the range of solutes eliminated during normal dialysis while keeping a small number of important proteins. Filtration is more similar to the natural kidney because of this particular cut-off and retention onset profile.

Why Purchase the Report?

Visualize the composition of the global hemodialysis bloodline systems market segmentation by product, therapy type, end user, and region highlighting the key commercial assets and players.

Identify commercial opportunities in global hemodialysis bloodline systems market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global hemodialysis bloodline systems market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global hemodialysis bloodline systems market report would provide an access to an approximately 40+ market data table, 45+ figures and 180 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Market Segmentation

Global Hemodialysis Bloodline Systems Market– By Product

Poly Vinyl Chloride Hemodialysis Bloodline Systems

Polyethylene Hemodialysis Bloodline Systems

Polypropylene Hemodialysis Bloodline Systems

ABS Hemodialysis Bloodline Systems

Global Hemodialysis Bloodline Systems Market- By Therapy Type

Double Needle Therapy

Single Needle Therapy

Single Needle Crossover

Haemodiafiltration

Global Hemodialysis Bloodline Systems Market– By End-User

Hospital

Clinics

Home Care Settings

Others

Global Hemodialysis Bloodline Systems Market- By Region

North America

Europe

Asia-Pacific

Middle East & Africa

South America


1. Global Hemodialysis Bloodline Systems Market Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Global Hemodialysis Bloodline Systems Market– Market Definition and Overview
3. Global Hemodialysis Bloodline Systems Market– Executive Summary
3.1. Market Snippet By Product
3.2. Market snippet By Therapy Type
3.3. Market Snippet by End User
3.4. Market Snippet by Region
4. Global Hemodialysis Bloodline Systems Market– Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise in prevalence of kidney disorders across the globe
4.1.1.2. Rise in geriatric population worldwide
4.1.2. Restraints:
4.1.2.1. High cost of advanced hemodialysis bloodline systems
4.1.2.2. Lack of skilled laboratory professionals hinder the growth of the market
4.1.2.3. Complications during dialysis can hinder the growth of the market
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Global Hemodialysis Bloodline Systems Market– Industry Analysis
5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Regulatory Analysis
6. Global Hemodialysis Bloodline Systems Market– COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. Global Hemodialysis Bloodline Systems Market– By Product
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Segment
7.1.2. Market Attractiveness Index, By Product Segment
7.2. Poly Vinyl Chloride Hemodialysis Bloodline*
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
7.3. Polyethylene Hemodialysis Bloodline Systems
7.4. Polypropylene Hemodialysis Bloodline Systems
7.5. ABS Hemodialysis Bloodline Systems
8. Global Hemodialysis Bloodline Systems Market– By Therapy Type
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
8.1.2. Market Attractiveness Index, By Therapy Type
8.2. Double Needle Therapy*
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
8.3. Single Needle Therapy
8.4. Haemodiafiltration
9. Global Hemodialysis Bloodline Systems Market– By End User
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User Segment
9.2. Hospital*
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
9.3. Clinics
9.4. Home Care Settings
9.5. Others
10. Global Hemodialysis Bloodline Systems Market– By Region
10.1. Introduction
10.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. U.K.
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
11. Global Hemodialysis Bloodline Systems Market– Competitive Landscape
11.1. Key Developments and Strategies
11.2. Company Share Analysis
11.3. Product Benchmarking
11.4. Key Companies to Watch
12. Global Hemodialysis Bloodline Systems Market- Company Profiles
12.1. Baxter*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Key Highlights
12.1.4. Financial Overview
12.2. Fresenius
12.3. B.Braun
12.4. Nipro
12.5. Nikkiso
12.6. Asahi KASEI Medical
12.7. Allmed
12.8. Bioteque
12.9. Sanxin
LIST NOT EXHAUSTIVE
13. Global Hemodialysis Bloodline Systems Market– DataM
13.1. Appendix
13.2. About Us and Services
13.3. Contact Us

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings